Achieving selectivity between highly homologous tyrosine kinases: A novel selective erbB2 inhibitor

Biochemical and Biophysical Research Communications

Volumn 307, Issue 2, 2003, Pages 267-273

  Bhattacharya, Samit K ^a   Cox, Eric D ^a   Kath, John C ^a   Mathiowetz, Alan M ^a   Morris, Joel ^a   Moyer, James D ^a   Pustilnik, Leslie R ^a   Rafidi, Kris ^a   Richter, Daniel T ^a   Su, Chunyan ^a   Wessel, Matthew D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE; RECOMBINANT ENZYME;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CHEMICAL STRUCTURE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

MAMMALIA;

EID: 0037676025     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01160-4     Document Type: Article

References (27)

1. Traxler P., Bold G., Buchdunger E., Caravatti G., Furet P., Manley P.et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21:2001;499-512.
2. Strawn L.M., Shawver L.K. Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp. Opin. Invest. Drugs. 7:1998;553-573.
3. Druker B.J. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8:2002;S14-S18.
4. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 241:1988;42-52.
5. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., Lydon N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Therap. 295:2002;139-145.
6. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A.et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:1997;4838-4848.
7. Prigent S.A., Lemoine N.R. The type 1(EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res. 4:1992;1-24.
8. Singh J., Dobrusin E.M., Fry D.W., Haske T., Whitty A., McNamara D.J. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40:1997;1130-1135.
9. Venter J.C.et al. The sequence of the human genome. Science. 291:2001;1304-1351.
10. Cohen B.D., Lowy D.R., Schiller J.T. Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain. J. Virol. 67:1993;5303-5311.
11. Fazioli F., Kim U.H., Rhee S.G., Molloy C.J., Segatto O., DiFiore P.P. The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Mol. Cell. Biol. 11:1991;2040-2048.
12. J.C. Kath, S.K. Bhattacharya, J. Morris, Preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth, PCT Int. Appl. (2001) (WO 0198277).
13. Stamos J., Slikowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:2002;46265-46272.
14. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P.et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960.
15. Palmer B.D., Trumpp-Kallmeyer S., Fry D.W., Nelson J.M., Showalter H.D.H., Denny W.A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. J. Med. Chem. 40:1997;1519-1529.
16. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R.et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1994;1093-1095.
17. Cockerill S., Stubberfield C., Stables J., Carter M., Gubtrip S., Smith K.et al. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg. Med. Chem. Lett. 11:2001;1401-1405.
18. Daly J.M., Jannot C.B., Beerli R.R., Graus-Porta D., Maurer F.G., Hynes N.E. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res. 57:1997;3804-3811.
19. Colomer R., Lupu R., Bacus S.S., Gelman E.P. ErbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br. J. Cancer. 70:1994;819-825.
20. Neve R.M., Sutterluty H., Pullen N., Lane H.A., Daly J.M., Krek W., Hynes N.E. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene. 19:2000;1647-1656.
21. Rusnak D.W., Affleck K., Cockerill S.G., Stubberfield C., Harris R., Page M.et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 61:2001;7196-7203.
22. Tsou H-.R., Mamuya N., Johnson B.D., Reich M.F., Gruber B.C., Ye F.et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 44:2001;2719-2734.
23. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K.D., Hicks J.L.et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA. 95:1998;12022-12027.
24. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur. J. Cancer. 37:2001;S16-22.
25. Perez-Soler R. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;310a.
26. Ciardiello F., Tortora G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7:2001;2958-2965.
27. McMahon G., Sun L., Liang C., Tang C. Protein kinase inhibitors: structural determinants for target specificity. Curr. Opin. Drug Discov. Dev. 1:1998;131-146.